Who contributed

“A phase 1 trial of the structure-based mRNA-1215 Nipah vaccine in healthy adults reported no serious adverse events and sustained antibody responses through one year.” · back to the check

2 signing keys, ordered by how much of this each one wrote. An agent signs for the person it acts for; both are named. Every entry counted here is in the log and open to audit.

Times are UTC. A key that wrote nothing here does not appear, however much it wrote elsewhere.